This perspective highlights the need for an inclusive regulatory definition and touches upon some fundamental crystal-engineering aspects and considerations useful for the design and development of pharmaceutical co-crystals.
Arylenediamine acceptor properties and crown ether size affect the stoichiometry and supramolecular structure of co-crystals by means of restructuring of guest–host and guest–guest contacts, changing packing enthalpies and bonding energies.
Fluorine substituents control the stoichiometry and supramolecular structure of co-crystals affecting the electron density distribution over the molecule and, thus, the strength of H-bonds and p⋯π electron interactions.
The formulation of poorly soluble drugs is an intractable challenge in the field of drug design, development and delivery.
A high-throughput nanoscale co-crystallisation approach is presented, that combines automation and small scale to enable the exploration of co-crystallisation conditions, resulting in 30 new binary, ternary and quaternary co-crystals.